


Journal Pre-proof

Development of a Web-based calculator to estimate DALY and Productivity Losses due to COVID-19

Denny John, M.S. Narassima, Paramita Bhattacharya, Nirmalya Mukherjee, Jaideep Menon, Amitava Banerjee



PII: S2213-3984(23)00275-0

DOI: <https://doi.org/10.1016/j.cegh.2023.101488>

Reference: CEGH 101488

To appear in: *Clinical Epidemiology and Global Health*

Received Date: 14 June 2023

Revised Date: 23 November 2023

Accepted Date: 14 December 2023

Please cite this article as: John D, Narassima MS, Bhattacharya P, Mukherjee N, Menon J, Banerjee A, Development of a Web-based calculator to estimate DALY and Productivity Losses due to COVID-19, *Clinical Epidemiology and Global Health* (2024), doi: <https://doi.org/10.1016/j.cegh.2023.101488>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 The Author(s). Published by Elsevier B.V. on behalf of INDIACLEN.

Title: Development of a Web-based Calculator to estimate DALY and Productivity Losses due to COVID-19

Running Title: Calculator for DALY and Productivity Losses

Author information:

1. Denny John
Centre for Public Health Research, Kolkata, India
Department of Public Health, Ramaiah University of Applied Sciences, Bengaluru, Karnataka, India.
<http://orcid.org/0000-0002-4486-632X>
2. M.S. Narassima
Great Lakes Institute of Management, Chennai, India
<http://orcid.org/0000-0002-4113-430X>
3. Paramita Bhattacharya
Assistant Director - Research, MANT, Kolkata, India
4. Nirmalya Mukherjee
Director and Head - MANT, Kolkata, India
5. Jaideep Menon
Department of Public Health, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, India
Department of Cardiology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, India
6. Amitava Banerjee
Institute of Health Informatics, University College London, London, UK
Department of Public Health, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, India

Corresponding Author details:

Name: Denny John

Address: Centre for Public Health Research, Kolkata, India

Email: djohn1976@gmail.com

Phone: +91 99870 21553

Number of words: 2886

Number of tables: 4

Number of figures: 2

Author Contributions:

The conception and design of the study, acquisition of data, or analysis and interpretation of data – DJ, MSN, PB, NM, JM, AB.

Drafting the article or revising it critically for important intellectual content – MSN, DJ, PB, NM, AB, JM.

Final approval of the version to be submitted – DJ, JM, AB.

Ethical statement:

The study has been conducted using publicly available data. No ethical approvals were sort for this study.

Journal Pre-proof

Development of a Web-based Calculator to estimate DALY and Productivity Losses due to COVID-19

Abstract

Objectives

Ever since the emergence of COVID-19, health and the economy worldwide have witnessed a severe disruption, with infection spreading rapidly, covering 231 countries as of May 07, 2023. Policymakers and Governments have been working to offer tailored interventions to the most vulnerable cohorts. Given this background, the paper involves description towards developing a Web-based Calculator to compute various estimates that quantify health economic impacts as these are much helpful than just mortality and simpler measures.

Methods

The computations required to determine the estimates and the variables involved have been picked based on the observations and literature. The manuscript presents the significance of the estimates, a description of the Calculator developed, followed by validation. The values estimated using Calculator were validated against those computed using formulas for the state of West Bengal, India.

Results

The results indicated that the Calculator is able to produce near accurate results with the highest error percentage witnessed for Cost of Productivity Lost due to Absenteeism as 0.946 percent. Error percentages for Disability-Adjusted Life Years was 0.175, and less than 0.1 for all other estimates.

Conclusions

This could prove to be an effective tool for the policymakers and practitioners to identify the long-term impacts and the most vulnerable cohorts and devise targeted interventions. Additionally, these tools will allow the policymakers and governments to save time in compute these estimates in the future.

Keywords

Disability-Adjusted Life Years, Cost of Productivity Lost, Years of Potential Productive Life Lost, Value of Statistical Life.


Introduction

COVID-19 has tormented the population health, healthcare systems and economies around the globe since its onset in December 2019. The pandemic has spread across 231 countries as of May 07, 2023, claiming 6,870,879 lives with 687,724,379 incidences and 660,201,450 recoveries¹. Such huge high-impact events need to be quantified to understand the magnitude of economic losses incurred². Measures such as Burden of Disease (BoD) measures, productivity loss, and Value of Statistical Life (VSL) help to quantify the impact of such events or diseases and to identify the most vulnerable cohorts for targeted interventions and policymaking^{3,4}. This is essential to cut down the losses incurred in health and economy for future pandemics.

Disability-Adjusted Life Years (DALY) is one of the most widely adopted public health measures that was developed for the Global Burden of Disease and Injury (GBD)⁵ study jointly by the World Health Organization (WHO), Harvard School of Public Health, and the World Bank^{2,3,6}. The associated productivity losses could be computed using Years of Potential Productive Life Lost (YPLL) and Cost of

41 Productivity Lost (CPL). The former measure computes the productive years lost, while the latter has
 42 sub-components to quantify permanent and temporary losses in terms of cost. The aforementioned
 43 alongside Years of Potential Life Lost (YPLL), Premature Years of Potential Life Lost (PYPLL), Working
 44 Years of Potential Life Lost (WYPLL), and Value of Statistical Life (VSL) help to quantify the losses and
 45 identify the potential cohorts contributing more to the losses. This is important as the disease has
 46 unequally impacted certain groups, including healthcare workers, comorbid people, etc. YPLL
 47 measures the life lived without the occurrence of the event compared with the life expectancy. Deaths
 48 at younger age groups are assigned higher weights and vice versa. PYPLL assesses premature death's
 49 social and economic impacts, considering the upper slab based on the study objective(s). WYPLL
 50 represents the working years lost by assigning a fixed weight for people before 15 years and varied
 51 weight for others, based on the difference between the upper age slab and mid-point of the cohort
 52 ^{3,7}. As policymaking needs to balance multiple dimensions like health, economy, and society
 53 considering these estimates, VSL was computed as the trade-off between survival and earning ^{3,4,8}.
 54 These estimates would interest policymakers, healthcare researchers, and practitioners to work
 55 alongside to devise tailored interventions. Additionally, it helps to understand the long-term impacts
 56 and most vulnerable cohorts. Also, the presence of a methodical guideline to compute these estimates
 57 might be helpful for the stakeholders.

58 With this background, the present study aims to present a step-by-step methodology to compute the
 59 above-mentioned estimates. DALY, YPPLL, CPL, YPLL, PYPLL, WYPLL, and VSL for COVID across the
 60 countries globally and various states of India. A web-based calculator has been developed to assist
 61 policymakers and researchers in instantaneously determining the estimates and measuring the
 62 population-level impact and impact on various cohorts. The Calculator has the flexibility to compute
 63 estimates of age-gender cohorts, i.e., for males and females of each age group defined by the user,
 64 which enhances its practical usefulness. The inputs that would be required and the trajectory of
 65 infection with respect to the estimates are presented in Figure 1.



67
68 Figure 1: Estimates and the trajectory of infection

69 **Research Methodology**

70 The methodology adopted could be majorly deconstructed into demographical and epidemiological
71 parameters. The former changes with the population characteristics and location being studied, while
72 the disease dynamics govern the latter. Some of the important aspects are discussed successively:

73 *Study area:*


74 Defining the geographical scope of the study and target population is primarily essential. This forms
75 the basis for the definition of several demographic as well as epidemiological parameters pertaining
76 to the population.

77 *Longitudinality:*

78 Defining the tenure of the study is needed to capture time series data, including incidence, deaths,
79 and hospitalized cases. Also, the time step to be chosen depends on the data availability. Largely, the
80 epidemiological data of COVID-19 are captured on a daily basis.

81 *Disease Model:*

82 A disease model explains the progress of the disease across various states. A state chart is used to
83 represent the disease model with all possible states of the existence of an infected person. Any
84 infected individual could be mapped to one and only one of these states at any point in time. The
85 transition between the states and duration of existence is purely based on the disease's influence on
86 several population cohorts. Outcome-based disease models distinguish the levels of severity of COVID-
87 19⁹. The State Chart indicating various states of the SHIVIR model is presented in Figure 2⁹. Several
88 other models developed include the Susceptible (S), Exposed (E), Symptomatic (I), Purely
89 Asymptomatic (P), Hospitalized or Quarantined (H), Recovered (R) and Deceased (D) (SIPHERD) by
90 Mahajan et al., (2020)¹¹, Susceptible (S), Exposed (E), Infective (I), and Recovered (R) (SEIR) model by
91 Zhang & Jain, (2020)¹², other Susceptible (S), Infective (I), and Recovered (R) based, Agent-based⁹, and
92 mathematical models¹².



93

94

Figure 2: State Chart of SHIVIR Model

95 Data Collection:

96 Data collection plays a vital role as the availability, accessibility, quality, and accuracy of data influence
 97 the reliability of the estimates. Also, the data gathered need to be fit as per the disease model failing
 98 which both have to be tuned to be synchronous with each other. Data could be gathered from peer-
 99 reviewed articles, grey literature, online reports and articles, government websites, preprint
 100 repositories, hospital observations, etc. Collecting data to the lowest level possible would yield specific
 101 results for various cohorts distinguished by age, gender, work status, location, etc. However,
 102 assumptions are to be made clearly in cases of data unavailability or inadequacy. Studies make
 103 assumptions; some of them made by John et al. (2021, 2023) include considering the same disability
 104 duration for male and female cohorts of a given age group, the retirement age of all working
 105 populations to be the same, the number of working days for all employees to be the same, etc. These
 106 lower-level estimates augment tailored interventions that are of interest to the policymakers. This
 107 also allows drawing inferences on the effect of each variable based on which data are distinguished.
 108 The collected data must be representative of the population/ region being studied with respect to
 109 time. Various demographic and epidemiological data required to compute the estimates have been
 110 tabulated (Table 1):

111

Table 1: Data collected and definitions

Parameter	Definition
Number of cases	Total number of incidence/ infections due to the disease i.e., COVID-19.
Number of deaths	Total number of deaths due to the disease i.e., COVID-19.

Proportion of mild cases	Cases that are asymptomatic/ mild; do not require hospitalization. They experience the least symptoms than other cohorts. They can be quarantined at houses/ health centers.
Proportion of moderate cases	Cases that require hospitalization. Additional disabilities, as compared to mild cases, could be attributed to these cases.
Proportion of critical cases	Cases that require critical care in hospitals. They represent the population with the highest disability. External oxygen support equipment might be required.
Time to recovery for mild and moderate cases	The duration between acquiring the disease and recovery. It might include either period of home isolation or a stay in the hospital.
Time of stay in critical care	Duration of stay in ICU or under external oxygen support.
Disability weights of the symptoms experienced	Disability weights indicate the level of disability associated with each symptom experienced by an infected individual.
Isolation period post-recovery	Quarantine is required after being tested negative/ recovery. This translates to an additional burden post-recovery (Assumption to enact Sensitivity Analysis).
Reduction in Life expectancy due to incidence	Incidence of the disease shortens the life expectancy (Assumption to enact Sensitivity Analysis).
Total population	People of all age groups within the scope of study in the location being studied.
Proportion of working population	Proportion of people from the total population who are employed and fall within the productive age groups.
Life expectancy at the age of death	Additional duration for which a person would have lived in the absence of premature mortality due to disease.
Discount rate for value of life	It is a measure used to indicate the risk at the workplace by trading-off health and the economy.
Discount rate (Financial benchmark)	A measure that gives the present value of future cash flows.
Age of retirement	Signifies the upper slab of the productive age group. Used to compute productivity losses.
Work days in a week	Number of productive days in a calendar week.
Per capita Net Domestic Product	Indicates the capital consumed by an individual in a year.

112

113 *Disability-Adjusted Life-Years*

114 DALY, one of the prominently used public health measures, is calculated as the sum of Years Lived
115 with Disability (YLD) and Years of Life Lost (YLL) ^{13,14}. The former component explains the loss due to
116 deaths, while the latter explains the loss due to incidence. The number of cases, which is one of the
117 primary inputs for DALY, could be obtained using three approaches, viz., direct, attribution, and
118 transition approaches. Given that the developed model is an outcome-based model, a direct
119 approach/ incidence-based approach in which the data would be available either in totality or based
120 on age, gender, and other features is appropriate. Considering the DW of different symptoms
121 experienced by the patients could bring in the influence of multimorbidity, thereby enhancing
122 accuracy ¹³. The Combined Disability Weights (CDW) could be determined by maximum limit,
123 multiplicative, and additive approaches as in equations (4) to (6) ¹³. A major proportion of the DALYs
124 are shared by YLL, which increases due to the younger population's higher mortality rate and/ or
125 higher mortality.

$$126 \quad YLD = \frac{I * DW * D (1 - e^{-rD})}{r} \quad (1)$$

127 where r = Discount for value of life; D = Disability duration (Time to recovery in years); I = Number of
128 cases

$$129 \quad YLL = \frac{N}{r} (1 - e^{-rL}) \quad (2)$$

130 where L = Life expectancy at the age of death (years); N = number of deaths.

$$131 \quad DALY = YLL + YLD \quad (3)$$

$$132 \quad DW_{ij} = DW_i + DW_j + \dots + DW_n \quad (4)$$

$$133 \quad DW_{ij} = 1 - (1 - DW_i) * (1 - DW_j) * \dots * (1 - DW_n) \quad (5)$$

$$134 \quad DW_{ij} = \max(DW_i, DW_j, \dots, DW_n) \quad (6)$$

135 where 'i', 'j', and 'n' indicate the various disabilities.

136 *Productivity Losses (YPPLL and CPL)*

137 YPPLL and CPL estimates due to an event determine the productivity losses considering the productive
138 years a person would have lived otherwise. Therefore, only those cohorts that represent the working
139 population are to be used to compute these estimates. The minimum employment and retirement
140 age denote the lower and upper slabs for the productive population. The temporary and permanent
141 loss components of CPL are due to absenteeism and premature mortality, respectively. They are often
142 computed using the human capital approach¹⁵.

$$143 \quad YPPLL = \sum_{i=1}^n D_i * w_i * d \quad | \quad i = 1, 2, \dots, n \quad (7)$$

144 Where 'i' iterates over 'n' cohorts; D_i = Number of deaths 'i'th cohort; w_i = Productive years remaining
145 at the age of death. Calculated as the difference between the cohort's retirement age and midpoint
146 age 'i' (years); d = Discount rate (Financial Benchmark). The discount rate is inapplicable to the first
147 year¹⁶.

$$148 \quad CPL = \sum_{j=1}^J YPPLL_j * \text{per capita GDP} * P \quad (8)$$

$$149 \quad CPL_{\text{absenteeism}} = \sum_{j=1}^J S * L_j * N_j * P_j \quad (9)$$

150 where S = daily salary; L_j = time to recover in 'j'th cohort; N_j = Incident cases in 'j'th cohort; P_j =
151 proportion of the working population in 'j'th cohort.^{17,18}

152 *Years of Potential Life Lost*

153 YPLL indicates the period for which an individual would have lived in the absence of an external event.
154 It is calculated based on life expectancy giving lower priorities to old-age deaths and vice versa.

$$155 \quad YPLL = \sum_{i=0}^{\infty} d_i \times L_i \quad (10)$$

156 where L_i is the life expectancy at age 'i' and d_i is the number of deaths in 'ith cohort.

$$157 \quad \text{Standardised } YPLL = YPLL \times \frac{P_{i,r}}{N_r} \times \frac{N}{P_i} \quad (11)$$

158 $P_{i,r}$ is the population in 'ith cohort and N_r is the overall population being studied. P_i is the population
159 infected in the 'ith cohort, and N is the infections in the overall population.

160 *Premature Years of Potential Life Lost*

161 PYPLL explains the social and economic impacts brought about by an event in the form of premature
162 deaths. The upper age limit depends on the purpose of the study. Life expectancy is considered in the
163 present study.

$$164 \quad PYPLL = \sum_{i=0}^U d_i \times (U - i) \quad (12)$$

165 d_i is the death at 'ith age, and U is the upper age limit. U is chosen based on the average life expectancy
166 of the population.

$$167 \quad \text{Standardised } PYPLL = PYPLL \times \frac{P_{i,r}}{N_r} \times \frac{N}{P_i} \quad (13)$$

168 $P_{i,r}$ is the population in 'ith cohort and N_r is the overall population below U. P_i is the population
169 affected in the 'ith cohort, and N is the overall infected population below U.

170 *Working Years of Potential Life Lost*

171 WYPLL refers to the losses incurred by the working population. Deaths of people aged below 15 carry
172 a fixed weight, 'W', while those for the other age groups are the difference between the upper age
173 limit and the midpoint of the age group considered.

$$174 \quad WYPLL = \sum_{i=0}^U d_i \times (R - W) + \sum_{i=0}^U d_i \times (R - i) \quad (14)$$

175 Where d_i is the deaths in 'ith age, R and W are the upper and lower slabs for the working population.

$$176 \quad \text{Standardised } WYPLL = WYPLL \times \frac{P_{i,r}}{N_r} \times \frac{N}{P_i} \quad (15)$$

177 $P_{i,r}$ is the population in 'ith cohort and N_r is the overall population studied. P_i is the infected
178 population in 'ith cohort, and N is the overall infections in the population.

179 *Value of Statistical Life*

180 VSL presents the rate of substitution between the survival possibility and earning. This is of much
181 importance for governments to perform risk monetization and cost-benefit analysis as the measures
182 consider health risk at the workplace based on the nature of work and personal attributes⁸. The Value
183 of Statistical Year and hence the VSL are computed as follows:

$$184 \quad VSLY_i = \frac{VSL_p}{L_i} \quad (16)$$

$$185 \quad VSL = \sum_{i=1}^U YPLL_i \times VSLY_i \quad (17)$$

186 Where VSL_p is the VSL of the population, $VSLY_i$ is the Value of Statistical Year of 'i'th cohort. However,
 187 the policymaking based on VSL and its Cost-benefit Analysis lacks grounding. The VSL estimates
 188 captured using the Value of Statistical Life Years (VSLY), population average, and textbook have
 189 differences. The textbook value is counterintuitive as richer individuals are assigned a higher risk
 190 reduction, and the population average treats all age groups equally ⁸.

191 **Data validation**

192 Acquiring data from trusted online websites, reports, official bulletins, published works, etc., could
 193 enhance the authenticity of the estimates ^{4,5,7,14,17-24}. Using rational, accepted techniques to compute
 194 the values supplements the accuracy of the estimates ^{2,14}. Standard approaches to include the effect
 195 of multimorbidity promotes accuracy by the inclusion of a range of symptoms experienced ¹³.
 196 Research by Rumisha et al. (2020), Wyper et al. (2021), Etheridge & Spantig (2020), and Dubey &
 197 Mohanty (2014) were much useful in computing the estimates. The CDWs were derived based on the
 198 suggestions by Hilderink et al. (2016). The value of life and discount rate for finance were used as given
 199 by Shanmugam (2011) and the Reserve Bank of India (RBI), respectively.

200 **Public involvement**

201 The methodology explained in this paper requires the use of secondary data. Hence, the involvement
 202 of the public/ patients might not be essential for any of the phases of research.

203 **Web-based Calculator**

204 The DALY and productivity losses assist policymakers in quantifying the impact of COVID-19 on the
 205 population. Some of the characteristics of the Calculator are discussed subsequently:

- 206 i. The Calculator allows the users to enter the variables separately for each age-gender cohort so as
 207 to determine and identify the most vulnerable ones to devise suitable intervention strategies.
- 208 ii. Though DALY is computed based on an incidence-based approach in the Calculator, its ability to
 209 capture specifics such as the number of cases, deaths, disability duration, and life expectancy for
 210 each age-gender cohort separately makes it possible for the policymakers to define different
 211 values of the variables for the cohorts of different levels of severity. i.e., the DALY estimates for
 212 mild, moderate, and critical patients can be computed by entering their respective incidence,
 213 deaths, and disability duration.
- 214 iii. Users can specify the symptoms experienced by the patients from the following: Cough, Fever/
 215 Chills, Shortness of breath, Myalgia, Diarrhea, Nausea/Vomiting, Sore throat, Headache, Chest
 216 pain, Abdominal pain, and Altered mental status/Confusion. The aforementioned symptoms are
 217 the ones experienced by people infected with COVID-19 ²⁸.
- 218 iv. Weighted scores are given to the DWs based on the proportion of people who were reported to
 219 have experienced each symptom.
- 220 v. CDWs are computed based on the chosen method presented in equations (4) to (6).

221 Calculation of productivity losses involves the following:

- 222 i. For YPPLL estimation, users are required to enter the retirement age, number of deaths, and
 223 discount rate for the required age group.
- 224 ii. The discount rate is applicable to all the years, excluding the first year during the computation of
 225 YPPLL.
- 226 iii. In addition to the values entered for computation of YPPLL, per capita GDP and proportion of the
 227 working population are required to compute the CPL due to premature mortality.

- 228 iv. For CPL, due to absenteeism, the number of working days and disability duration is additionally
229 required.
- 230 v. The total population and the total population affected by the disease in the cohort being studied,
231 the number of deaths and life expectancies are required to compute YPLL, PYPLL, and WYPLL.
- 232 vi. The Value of Statistical Year is required to compute VSL.

233 **Validation based on Calculator**

234 To validate the methodology employed and the working of the Calculator, the estimates were
235 computed using the formulas presented in equations (1) to (17) in Excel according to the original
236 source paper to ensure consistency of outputs and also using the calculator³. The data considered by
237 John et al. (2023) to compute the estimates for West Bengal were used for validation. The following
238 tables provide the data used for computing the estimates, the values obtained using the formula,
239 Calculator, and the difference between the computed values. The differences between the values
240 computed in Tables 2 to 4 are negligibly small and associated with rounding off decimal places. Table
241 2 shows the overall DALY computed for Male and Female cohorts, YPLL, Standardized YPLL, and VSL
242 for Male cohorts. YPPLL, CPL – Premature Mortality and CPL – Absenteeism in Table 3 are for Female
243 cohorts, whereas the estimates in Tables 4 are for Male cohorts. A screenshot of the computation
244 using the Calculator are provided in Figure 3 as an example. All other computations with screenshots
245 have been uploaded onto the link
246 https://osf.io/4w72v/?view_only=46e7b450f2bf4eeda798dd727dcb93ac. The Web-based Calculator
247 can be accessed at <http://covidaly.cphr-mant.org/index.php>.

248

249

250

Table 2: DALY (YLD and YLL), YPLL, Standardized YPLL, and VSL

Age	Deaths		Cases		Life Expectancy	Life Expectancy	Population	Disability days	YLL (Discounted)		YLD		DALY		YPLL (Male)	Standardized YPLL (Male)	VSL (INR million) (Male)
	Male	Female	Male	Female					Male	Female	Male	Female	Male	Female			
0-15	38	22	45744	38260	71.65	70.7	11745401	15.13	1146.3	663.6	20.25	16.94	1166.5	680.6	2686.60	12197.04	1697.90
16-30	194	144	160102	188113	59.05	58	15574298	13.64	5482.7	4069.6	57.61	67.68	5540.3	4137.3	11252.00	19353.49	8675.30
31-45	1042	507	256164	205648	44.8	43.7	12004110	14.29	26130.8	12714.3	101.16	81.21	26232.0	12795.5	45535.40	37729.31	46582.70
46-60	3217	1928	199442	192895	30.85	30	7916504	14.21	65587.9	39307.9	77.88	75.32	65665.8	39383.2	96510.00	67734.04	143799.90
61-75	5269	2994	185719	134708	18.55	17.9	3673672	15.85	75593.1	42954.2	90.22	65.44	75683.3	43019.6	94315.10	32987.02	235504.80
75+	2614	1895	67700	37463	8.95	8.6	827870	14.63	20605.7	14937.9	28.02	15.51	20633.7	14953.4	22480.40	4860.66	116830.60
Using Formula									194546.4	114647.6	375.14	322.10	194921.6	114969.7	272779.50	174861.58	553091.20
Calculator									194868.6	114848.8	375.14	322.10	195243.7	115170.9	272779.5	174861.4	553091.28
Error Percentage									0.17	0.18	0	0	0.17	0.18	0.06	0.000106	1.46E-05

251 Figure 3: Screenshot of DALY (YLD and YLL)



252

253 Table 3: YPPLL and CPL (Premature Mortality and Absenteeism)

Age	Midpoint age	Working population (%)	Cases	Disability Duration	Deaths	YPPLL	CPL – Premature Mortality	CPL – Absenteeism
16-30	23	21.25	188113	13.64	144	1190.76	30680760.97	182870088.1
31-45	38	31.55	205648	14.29	507	4654.07	178050116.85	310833606.6
46-60	53	29.39	192895	14.21	1928	10513.53	374754672.43	270017191.3
					Using Formula	16358.37	583485550.26	763720886.1
					Calculator	16358.372	583454983.12	756493399.6
					Error Percentage	2.04213E-07	0.005	0.946

254 Table 4: PYPLL, Standardized PYPLL, WYPLL, and Standardized WYPLL

Age	Cases	Deaths	Population	Mid-Pt Age	PYPLL	Standardized PYPLL	WPYPLL	Standardized WYPLL	
0-15	45744	38	11745401	7.5	2396.68	10239.58	1706.50	6135.21	
16-30	160102	194	15574298	23	9249.98	14972.18	7175.03	9772.82	
31-45	256164	1042	12004110	38	34089.49	26580.70	22934.83	15048.49	
46-60	199442	3217	7916504	53	56937.27	37605.16	22517.56	12514.80	
61-72	185719	5269	3673672	66.5	22129.64	7283.71			
					Using Formula	124803.06	96681.33	54333.92	43471.32
					Calculator	124799.5	96698.26	54331	43481.55
					Error Percentage	0.0028	0.0175	0.005	0.023

255

256

257 Future directions

258 We will continue to work on our DALY calculator to extend to other diseases such as cardiovascular
259 diseases, oral cancer, and mental illness, which is currently underway.

260

261 Implications

262 While other calculators exist for calculating DALYs none are able to estimate to estimate the complex
263 disease pathway involving COVID-19 (see Figure 1)^{6,29,30}. While previous calculators have used web-
264 based interfaces which are user-friendly^{6,30}, ours is the only calculator for use for COVID-19 but also it
265 various extensions such as YPPLL, CPL, YPLL, PYPLL, WYPLL, and VSL.

266 Economic evidence, such as incremental cost-effectiveness ratios, can be used to prioritize resource
267 allocation decisions. To improve comparability across studies in various disease areas the practice
268 guidelines in economic evaluations recommend using generic measures of health outcomes, such as
269 quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs). The DALY, a measure of
270 disease burden that captures both reductions in life expectancy and quality of life due to disability,
271 has been increasingly used in economic evaluations, particularly studies for India and other low-
272 middle income countries (LMICs). However, many studies still measure and report the study findings
273 in the disease-specific units, such as COVID-19 cases averted, limiting the comparability of study
274 findings across disease areas. (e.g., which intervention is more cost-effective: \$100 per COVID-19 case
275 averted vs. \$100 per TB case averted?).

276 A decision-maker, particularly in India and other LMICs where data scarcity is a common problem,
277 would like to use all of the existing information in their resource prioritization. To help this process,
278 we developed a tool that can convert COVID-19 health outcomes expressed in non-DALY metrics (e.g.,
279 cases or deaths averted) into DALYs. Converted DALY measures can then be used to compare cost-
280 effectiveness ratios of interventions comparing COVID-19 and across different disease areas.

281

282 Limitations

283 The web-based calculator was developed using data available from published sources. However, it
284 might be that data will not be available. For example, in our paper estimating DALYs for COVID-19 in
285 Kerala we had to assume that the percentage deviations in the distribution of cases for each age-
286 gender cohort in India for 2020 and 2021 and those of Kerala were assumed to be similar (2). In cases
287 of missing data of certain input values for a particular state in Kerala or any other country suitable
288 assumptions will need to be made.

289 The study has used the human capital approach and taken into account the impact of multimorbidity
290 depending on the different symptoms encountered. For the purpose of calculating DALY, three
291 different approaches to calculating CDW have been considered. The cohorts producing greater
292 financial losses can be identified with the aid of productivity losses like YPPLL and CPL brought on by
293 early mortality and morbidity. While WYPLL and VSL provide work-related losses, YPLL and PYPLL give
294 losses based on life expectancies. VSL facilitates decision-making by clarifying the health risks
295 connected with labour and the corresponding income. The availability of data and the reliability of the
296 sources determine the estimates' accuracy and level of detail. The report also explains the necessary
297 inputs and how they are used to calculate these estimations. It is important to take into account the
298 difference in Kaldor-efficiency Hick's between CBA and VSL since the former highlights Pareto

299 superiority while the latter gauges willingness to pay. Because of this ideological disparity, results for
300 higher risks, such as COVID-19⁸, may be erroneous. This could be useful when utilising the web-based
301 calculator to calculate estimates instantly.

302

303 **Conclusions**

304 The current work offers a logical procedure and an explanation of a web-based calculator that can be
305 used to calculate COVID-19 productivity losses and DALYs. Rather than depending solely on mortality
306 and less complex metrics, politicians, academicians, and others may find this to be a useful tool in
307 carefully predicting the long-term effects and identifying the critical/vulnerable cohorts that
308 contribute more to the losses. The use of the web-based calculators free up more time for
309 governments and policymakers to address crisis circumstances more effectively by cutting down on
310 the time they need to calculate estimates and develop analytical approaches. When diseases or
311 occurrences occur often within a community and require specialised care, these techniques may come
312 in useful.

313 **Statements and Declarations**

314 The authors declare that they have no known competing financial interests or personal relationships
315 that could have appeared to influence the work reported in this paper.

316 **Funding**

317 No funding was received for conducting this study.

318 **References**

- 319 1. Worldometer. Coronavirus Cases. Worldometer. doi:10.1101/2020.01.23.20018549V2
- 320 2. John D, Narassima MS, Menon J, Rajesh JG, Banerjee A. Estimation of the economic burden of
321 COVID-19 using disability-adjusted life years (DALYs) and productivity losses in Kerala, India: a
322 model-based analysis. *BMJ Open*. 2021;11(8):e049619. doi:10.1136/BMJOPEN-2021-049619
- 323 3. John D, Narassima MS, Bhattacharya P, Mukherjee N, Banerjee A, Menon J. Model-based
324 estimation of burden of COVID-19 with disability-adjusted life years and value of statistical
325 life in West Bengal, India. *BMJ Open*. 2023;13(1):e065729. doi:10.1136/bmjopen-2022-
326 065729
- 327 4. Majumder A, Madheswaran S. Value of Statistical Life in India: A Hedonic Wage Approach.
328 2018;(March 2018):Working Paper 407, ISBN 978-81-7791-263-0.
- 329 5. Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause
330 mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic
331 analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016;388(10053):1459-1544.
332 doi:10.1016/S0140-6736(16)31012-1
- 333 6. CBRA. DALY Calculator. Center for Burden and Risk Assessment. Published 2015. Accessed
334 February 12, 2023. <https://daly.cbra.be/?main=home>
- 335 7. Dubey M, Mohanty SK. Age and sex patterns of premature mortality in India. *BMJ Open*.
336 2014;4(8):1-9. doi:10.1136/bmjopen-2014-005386
- 337 8. Adler MD. What Should We Spend to Save Lives in a Pandemic? A Critique of the Value of
338 Statistical Life. *Duke Law Sch Public Law Leg Theory Ser*. 2020;(2020-40).
339 doi:10.2139/SSRN.3636550
- 340 9. Narassima MS, John D, Anbuudayasankar SP, et al. An agent-based model to assess
341 coronavirus disease 19 spread and health systems burden. *Int J Electr Comput Eng*.
342 2022;12(4):4118-4128. doi:10.11591/ijece.v12i4.pp4118-4128

- 343 10. Mahajan A, Sivadas NA, Solanki R. An epidemic model SIPHERD and its application for
 344 prediction of the spread of COVID-19 infection in India. *Chaos, Solitons and Fractals*.
 345 2020;140(1):110156. doi:10.1016/j.chaos.2020.110156
- 346 11. Zhang Z, Jain S. Mathematical model of Ebola and Covid-19 with fractional differential
 347 operators: Non-Markovian process and class for virus pathogen in the environment. *Chaos,*
 348 *Solitons and Fractals*. 2020;140(1):110175. doi:10.1016/j.chaos.2020.110175
- 349 12. Ambikapathy B, Krishnamurthy K. Mathematical modelling to assess the impact of lockdown
 350 on COVID-19 transmission in India: Model development and validation. *J Med Internet Res*.
 351 2020;22(5):1-8. doi:10.2196/19368
- 352 13. Hilderink HBM, Plasmans MHD, Snijders BEP, Boshuizen HC, René Poos MJJC, van Gool CH.
 353 Accounting for multimorbidity can affect the estimation of the Burden of Disease: A
 354 comparison of approaches. *Arch Public Heal*. 2016;74(37):1-16. doi:10.1186/s13690-016-
 355 0147-7
- 356 14. Jo MW, Go DS, Kim R, et al. The burden of disease due to COVID-19 in Korea using disability-
 357 adjusted life years. *J Korean Med Sci*. 2020;35(21):1-10. doi:10.3346/jkms.2020.35.e199
- 358 15. Kirch W, ed. Human Capital Approach. In: *Encyclopedia of Public Health*. Springer
 359 Netherlands; 2008:697-698. doi:10.1007/978-1-4020-5614-7_1583
- 360 16. Michael F. D, Mark J. S, Karl C, Greg L. S, George W. T. *Methods for the Economic Evaluation*
 361 *of Health Care Programmes*. Fourth Edi. Oxford University Press; 2015.
- 362 17. Phua J, Weng L, Ling L, et al. Intensive care management of coronavirus disease 2019 (COVID-
 363 19): challenges and recommendations. *Lancet Respir Med*. 2020;8(5):506-517.
 364 doi:10.1016/S2213-2600(20)30161-2
- 365 18. Rees EM, Nightingale ES, Jafari Y, et al. COVID-19 length of hospital stay: A systematic review
 366 and data synthesis. *BMC Med*. 2020;18:1-22. doi:10.1186/s12916-020-01726-3
- 367 19. Ock M, Lee JY, Oh IH, Park H, Yoon SJ, Jo MW. Disability weights measurement for 228 causes
 368 of disease in the Korean burden of disease study 2012. *J Korean Med Sci*. 2016;31(Suppl
 369 2):S129-S138. doi:10.3346/jkms.2016.31.S2.S129
- 370 20. Etheridge B, Spantig L. Covid Economics a Critique of the Value of Statistical Life Gender Gap
 371 in Mental Well-Being Inequality During the 1918 Influenza Investors Reward Environmental
 372 Responsibility. *CEPR Press COVID Econ*. 2020;(33):46-72. <https://portal.cepr.org/call-papers->
 373 Office of the Registrar General & Census Commissioner. Ministry of Home Affairs,
 374 Government of India. Published 2020. Accessed September 12, 2020.
 375 <https://censusindia.gov.in/>
- 376 22. Team CODD-K. covid19kerala.info. GitHub. Published 2020. Accessed August 30, 2020.
 377 <https://team.covid19kerala.info/>
- 378 23. Kumar S, Gosain M, Sharma H, et al. Who interacts with whom? Social mixing insights from a
 379 rural population in India. Lau EH, ed. *PLoS One*. 2018;13(12):e0209039.
 380 doi:10.1371/journal.pone.0209039
- 381 24. Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the Global Burden of Disease
 382 2013 study. *Lancet Glob Heal*. 2015;3(11):e712-e723. doi:10.1016/S2214-109X(15)00069-8
- 383 25. Rumisha SF, George J, Bwana VM, Mboera LEG. Years of potential life lost and productivity
 384 costs due to premature mortality from six priority diseases in Tanzania, 2006-2015. *PLoS One*.
 385 2020;15(6):2006-2015. doi:10.1371/journal.pone.0234300
- 386 26. Wyper GMA, Assunção RMA, Colzani E, et al. Burden of Disease Methods: A Guide to
 387 Calculate COVID-19 Disability-Adjusted Life Years. *Int J Public Health*. 2021;66(October):1-7.
 388 doi:10.3389/ijph.2021.619011
- 389 27. Shanmugam KR. Discount Rate for Health Benefits and the Value of Life in India. *Econ Res Int*.
 390 2011;2011(ID 191425):1-5. doi:10.1155/2011/191425
- 391 28. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients
 392 Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States,
 393 March 1–30, 2020. *Morb Mortal Wkly Report, US Dep Heal Hum Serv Dis Control Prev*.

- 394 2020;69(15):458-464.
- 395 29. CEVR. DALY Calculator. CEVR Tufts Medical Center. Published 2023.
- 396 <https://cevr.shinyapps.io/DALYcalculation/>
- 397 30. ECDC. Toolkit - Application to calculate DALYs. European Centre for Disease Prevention and
- 398 Control. Published 2023. [https://www.ecdc.europa.eu/en/publications-data/toolkit-](https://www.ecdc.europa.eu/en/publications-data/toolkit-application-calculate-dalys)
- 399 [application-calculate-dalys](https://www.ecdc.europa.eu/en/publications-data/toolkit-application-calculate-dalys)
- 400

Journal Pre-proof

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Journal Pre-proof